| Date | Title | Description |
| 28.03.2023 | Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes | Redwood City, CA — March 28, 2023 — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients ... |
| 06.03.2023 | BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-Related Adverse Even... | Palo Alto, CA — March 06, 2023 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced positive results from PROPEL2, a Phase 2 trial of the ... |
| 09.02.2023 | Spruce Biosciences Announces $53.6 Million Private Placement Financing | South San Francisco, CA — Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today anno... |
| 07.02.2023 | Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform | CAMBRIDGE, MA.– Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced a $62 million Series B financing led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset ... |
| 05.01.2023 | Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan | San Francisco, CA & TOKYO – Jan 5, 2023 – Spruce Biosciences, Inc. (Nasdaq: SPRB) and Kaken Pharmaceutical Co. Ltd (Tokyo Stock Exchange: 4521) today announced that the companies have entered into an exclusive licensing agreement for th... |
| 20.12.2022 | Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD | LONDON and RALEIGH, NC – December 20, 2022 – Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), today announces positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatmen... |
| 14.12.2022 | Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Waltham, MA — December 14, 2022 — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing o... |
| 05.12.2022 | Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia | WALTHAM, MA – December 5, 2022 – Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA)... |
| 01.11.2022 | Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors | BOSTON, MA — November 1, 2022 — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company has dosed the first patient in its Phase 1/2 c... |
| 31.10.2022 | Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219 | REDWOOD CITY, CA – Oct. 31, 2022 — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients w... |
| 17.10.2022 | Treeline Biosciences - An Update From Our Founders | October 17, 2022
“Homo sapiens is a storytelling animal that thinks in stories rather than in numbers or graphs, and believes that the universe itself works like a story, replete with heroes and villains, conflicts and resolutions, climaxe... |
| 27.09.2022 | Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients | COLUMBUS, OH — September 27, 2022 — Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the new availability of plasmid DNA manufacturing to its suite of scalable manufacturing servic... |
| 12.09.2022 | Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms | • Total capital raised of $330 million since the Company’s launch in 2020
• Financing expands planned usage of Company’s 20 cGMP suites containing multiple 50L, 500L, 1,000L and 5000L bioreactors for research-to-commercial gene therapy man... |
| 15.08.2022 | Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs | LONDON and RALEIGH, NC — August 15, 2022 — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the closing of its upsized public of... |
| 09.08.2022 | Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD | LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), today announces its top-line Phase 3 ENHANCE-2 (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) trial ... |
| 03.08.2022 | Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies | Leveraging Poseida’s novel approach to cell therapy and Roche’s expertise in developing and commercializing therapies to transform cancer care, the collaboration is focused on advancing multiple existing and additional next generation allog... |
| 28.07.2022 | Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group | Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801)
Expands pipeline to now include two clinical stage precision oncology candidates for patients with genomically defined solid tumors, ... |
| 27.07.2022 | Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S. | Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validation
Melint... |
| 14.06.2022 | Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis P... | – Momentum continues to build for Dren Bio after successfully forming highly experienced senior leadership team and earlier this year announcing research collaboration and license deal with Pfizer
– The financing round was co-led by Aislin... |
| 13.06.2022 | BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) | -Treatment with encaleret resulted in rapid and sustained restoration of normal mineral homeostasis, with mean values of blood calcium, urinary calcium, and blood PTH within the normal range by day 5 of therapy and sustained at 24 weeks, an... |
| 13.05.2022 | BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years | –Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021 for $110 million
–Secured a two-year extension of interest-only period on its existing senior secured credit... |
| 05.04.2022 | Atreca Announces Expansion of Preclinical Pipeline | Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate
SAN CARLOS, CA — April 05, 2022 — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused... |
| 03.04.2022 | BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | PALO ALTO, CA – April 3, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced updated data from its ongoing Phase ... |
| 31.03.2022 | CIDARA THERAPEUTICS ANNOUNCES THE COMPLETION OF DOSING THE FIRST COHORT OF HEALTHY VOLUNTEERS IN THE PHASE 1 TRIAL OF CD388 IN DEVELOPMENT FOR UNIVERSAL PREVENTION AND TREATMENT OF SEASONAL AND PANDEM... | SAN DIEGO, CA – March 31, 2022 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that ... |
| 30.03.2022 | Antios Therapeutics’ ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies | DOYLESTOWN, PA – March 30, 2022 – Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced new data from the Phase 1b a... |
| 29.03.2022 | Prolacta - Independent, head-to-head study shows significant health benefits of early fortification associated with Prolacta Bioscience’s 100% human milk-based fortifiers compared to cow milk-based fo... | DUARTE, CA- March 29, 2022 – An independent, head-to-head study from Neuburg, Germany, shows extremely low birth weight preterm infants fed Prolacta Bioscience® 100% human milk-based fortifiers (HMBF) as part of an Exclusive Human Milk Diet... |
| 25.03.2022 | ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months | RAMSEY, NJ and BOCA RATON, FL – March 25, 2022 — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, annou... |
| 24.03.2022 | ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management | RAMSEY, NJ and BOCA RATON, FL – March 24, 2022 — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived... |
| 22.03.2022 | ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe End... | GENEVA, Switzerland – March 22, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced additional efficacy results from the Phase 3 EDELWEIS... |
| 17.03.2022 | AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update | CAMBRIDGE, MA.- March 17, 2022– AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year e... |
| 15.03.2022 | Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL | ST. LOUIS, MO and SAN DIEGO, CA – March 15, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announc... |
| 14.03.2022 | Elevation Oncology Appoints David Dornan, Ph.D., as Chief Scientific Officer | NEW YORK, NY – March 14, 2022 — Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the appoint... |
| 14.03.2022 | BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) | PALO ALTO, CA – March 14, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and its affiliate company ML Bio Solutions, today a... |
| 14.03.2022 | James Brady Joins Verona Pharma as Non-Executive Director | LONDON and RALEIGH, NC – March 14, 2022 — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces Mr. James Brady has joined the board as a Non-Executive Dire... |
| 08.03.2022 | BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin) | Palo Alto and Solana Beach, CA – March 8, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-... |
| 07.03.2022 | ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA | RAMSEY, NJ and BOCA RATON, FL and CONYERS, GA – March 07, 2022 — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived ... |
| 03.03.2022 | Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update | SAN CARLOS, CA – March 03, 2022 — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human... |
| 03.03.2022 | Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. | Lugano, Switzerland and Palo Alto, CA – March 3, 2022 — Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and Bri... |
| 28.02.2022 | Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update | NEW YORK, NY – February 28, 2022 – Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial res... |
| 23.02.2022 | Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations | SAN DIEGO, CA – February 23, 2022 — Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity... |
| 16.02.2022 | MARKER THERAPEUTICS ANNOUNCES CLINICAL PROGRAM UPDATES AND PIPELINE EXPANSION | HOUSTON, TX – February, 16, 2022 — Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignan... |
| 14.02.2022 | CIDARA THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR CD388 FOR UNIVERSAL PREVENTION AND TREATMENT OF INFLUENZA | SAN DIEGO, CA – February 14, 2022 — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that th... |
| 10.02.2022 | ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix | GENEVA, Switzerland – February 10, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced a strategic licensing agreement with Theramex, a l... |
| 09.02.2022 | AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis | CAMBRIDGE, MA – February 9, 2022 — AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported interim data from a collaborator-sponsore... |
| 08.02.2022 | Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants | FREMONT, CA- February 08, 2022 — Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting ... |
| 01.02.2022 | AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer | CAMBRIDGE, MA – February 1, 2022 — AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean O’Bryan as chief... |
| 31.01.2022 | Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors | SAN DIEGO, CA – January 31, 2022 — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the first patient has been dosed in the multinational Phase 1b/2 trial ... |
| 27.01.2022 | BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) | PALO ALTO, CA – January 27, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been d... |
| 25.01.2022 | Biomea Fusion Announces First Patient Dosed | REDWOOD CITY, CA – January 25, 2022 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), today announced that the first patient has been dosed in its Phase I clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor... |
| 25.01.2022 | Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degrader... | BOSTON, MA and REHOVOT, Israel – January 25, 2022 — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, announced a license and research collaboration agreement with Dr. ... |
| 24.01.2022 | Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD | LONDON and RALEIGH, NC – January 24, 2022 — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed patient enrollment... |
| 20.01.2022 | Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors | NEW YORK, NY – January 20, 2022 — Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S.... |
| 19.01.2022 | MARKER THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ITS MULTI-ANTIGEN TARGETED T CELL THERAPY FOR PANCREATIC CANCER | HOUSTON, TX – January 19, 2022 — MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignanci... |
| 18.01.2022 | ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC | RAMSEY, NJ, BOCA RATON, FL and GOOSE CREEK, SC – January 18, 2022 — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-deriv... |
| 13.01.2022 | BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12... | PALO ALTO, CA – January 13, 2022 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a non-exclusive clinical collaboration with Amgen In... |
| 10.01.2022 | Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021 | DUBLIN, Ireland and FORT WASHINGTON, PA – January 10, 2022 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat... |
| 06.01.2022 | ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain | GENEVA, Switzerland – January 6, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced positive topline results from the Phase 3 EDELWEISS ... |
| 06.01.2022 | Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes | REDWOOD CITY, CA – January 6, 2022 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of irreversible small molecules to treat and improve the lives of pati... |
| 05.01.2022 | Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular I... | FREMONT, CA – January 05, 2022 — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data in an article titled, “Immunogenicity and Safety of Inactiv... |
| 05.01.2022 | Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset | LONDON and RALEIGH, NC – January 05, 2022 — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces enrollment completed in the 48-week subse... |
| 04.01.2022 | AVROBIO Reprioritizes Pipeline Programs | CAMBRIDGE, MA – January 4, 2022 — AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that it is shifting its portfolio priorit... |
| 03.01.2022 | Novo Holdings to acquire Medical Knowledge Group | Denmark – January 03, 2022 – Novo Holdings A/S (“Novo Holdings”), a leading global life sciences investor, today announced that it has agreed to acquire Medical Knowledge Group from Court Square Capital and Aisling Capital. Medical Knowledg... |
| 27.12.2021 | BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study | PALO ALTO, CA – December 27, 2021 — BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced topline results from Month 12 (Part A) of ATTRibute-CM, an ongoing global Phase 3 study investigating acoramidis for the treatment of symptomatic tran... |
| 21.12.2021 | ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases | Ardsley, NY – December 20, 2021 – ARMGO Pharma Inc (“ARMGO”), a leading novel small molecule therapeutics company developing treatments for cardiac, musculoskeletal, and neurological disorders today announced that it has completed a $35 mil... |
| 20.12.2021 | ObsEva Added to the NASDAQ Biotechnology Index | GENEVA, Switzerland – December 20, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced it has been selected for addit... |
| 20.12.2021 | Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors | SAN DIEGO, CA – December 20, 2021 — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity... |
| 17.12.2021 | Harmony Biosciences to be Added to the Nasdaq Biotech Index | PLYMOUTH MEETING, PA – December 17, 2021– Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases,... |
| 16.12.2021 | Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index | SAN DIEGO, CA – December 16, 2021 — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (N... |
| 15.12.2021 | Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme | NEW YORK, NY – December 15, 2021 — Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S... |
| 14.12.2021 | ews Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Viru... | MENDHAM, NJ and WARMINSTER, PA – December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients w... |
| 14.12.2021 | Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus In... | MENDHAM, NJ and WARMINSTER, PA – December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients w... |
| 13.12.2021 | Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer | NEW YORK, NY – Dec. 13, 2021 — Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S. Fo... |
| 11.12.2021 | Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease | WALTHAM, MA – December 11, 2021 — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated posit... |
| 09.12.2021 | Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab | WALTHAM, MA – December 09, 2021 — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and licens... |
| 08.12.2021 | Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer | NEW YORK, NY – Dec. 8, 2021– Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S. Food... |
| 06.12.2021 | Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency | AUSTIN, TX – December 6, 2020 — Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announce... |
| 01.12.2021 | Prolacta Bioscience enrolls first infant in Japan-based clinical trial to evaluate the effect of an Exclusive Human Milk Diet on growth and safety in premature infants | DUARTE, CA – Dec. 01, 2021 — Prolacta Bioscience®, the world’s leading hospital provider of 100% human milk-based nutritional products for premature and critically ill infants, today announced the enrollment of the first baby into a Japan-b... |
| 23.11.2021 | Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma | BOSTON, MA and LOUISVILLE, KY – November 30, 2021 – Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantat... |
| 22.11.2021 | Prolacta Bioscience Appoints Dr. Anne Beal to Board of Directors | DUARTE, CA – November 22, 2021 — Prolacta Bioscience®, the world’s leading hospital provider of 100% human milk-based nutritional products for premature and critically ill infants, today announced that Dr. Anne Beal, founder and CEO of Abso... |
| 22.11.2021 | Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix | FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – November 22, 2021 – Obseva SA (NASDAQ... |
| 19.11.2021 | BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types | Palo Alto, CA, and Lugano, Switzerland – November 19, 2021 – BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, and Helsinn Group, a fully integrated, global biopharm... |
| 15.11.2021 | ews Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs) | MENDHAM, NJ and ROME, ITALY – November 15, 2021 – Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery... |
| 10.11.2021 | Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates | BOSTON, MA – November 10, 2021 — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue-based precision medicines, today reported business highlights and financial results for the third quarter... |
| 03.11.2021 | Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV | MENDHAM, NJ – November 03, 2021 — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced the successful closing of ... |
| 29.10.2021 | Prolacta Bioscience Develops World’s First Test to Directly Detect Bacteria and Viruses, Including SARS-CoV-2, in Donor Breast Milk | DUARTE, CA – October 29, 2021 – Prolacta Bioscience®, the world’s leading hospital provider of 100% human milk-based nutritional products, announced today that it has developed the first nucleic acid amplification test (NAAT) capable of dir... |
| 21.10.2021 | Harmony Biosciences to be Added to the S&P SmallCap 600® Index | PLYMOUTH MEETING, PA – Oct. 21, 2021 – Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY)(“Harmony” or the “Company”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurologi... |
| 12.10.2021 | Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies | Collaboration to leverage Poseida’s non-viral piggyBac® DNA Modification System, Cas-CLOVER™ Site-Specific Gene Editing System, biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms
C... |
| 27.09.2021 | Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases | Syndax to receive $ 152 million in cash ($117 million upfront plus a $35 million equity investment, with potential for $450 million in additional milestone payments; 50:50 profit share in the U.S. and double-digit royalties on ex-U.S. sales... |
| 23.09.2021 | Garuda Therapeutics Launches with $72 Million Series A Financing | CAMBRIDGE, MA – September 23, 2021 – Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, launched today with an oversubscribed $72 million Series A financing led by Aisling Capital, Northpond Ventures a... |
| 27.07.2021 | BridgeBio Announces Clinical Collaboration With Bristol Myers Squibb To Study BBP-398, A Potentially Best-In-Class SHP2 Inhibitor, In Combination With OPDIVO® (Nivolumab) In Advanced Solid Tumors With... | First clinical combination study set to evaluate safety and preliminary efficacy in non-small cell lung cancer with KRAS mutations
PALO ALTO, CA – July 27, 2021 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopha... |
| 15.07.2021 | Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials | Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications.
Oversubscribed Series B co-led by Abingworth and Tybourne Capital Management, and joined by Fidelity Managem... |
| 29.06.2021 | Reneo Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices | SAN DIEGO, CA – June 29, 2021 – Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, joined ... |
| 24.06.2021 | Elevation Oncology Announces Pricing of Initial Public Offering | NEW YORK, NY – June 24, 2021 – Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the pricing ... |
| 23.06.2021 | Monte Rosa Therapeutics Announces Pricing of Initial Public Offering | Boston, MA – June 23, 2021 – Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeut... |
| 10.06.2021 | Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China | $40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties Nuance Ph... |
| 08.06.2021 | Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis | TI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4
Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach
ATI-1777 was Generally Well Tolerated
Data Support Progression to Phase 2b... |
| 28.05.2021 | BridgeBio Pharma’s Affiliate QED Therapeutics And Partner Helsinn Group Announce FDA Approval Of TRUSELTIQ™ (Infigratinib) For Patients With Cholangiocarcinoma | Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement
Bri... |
| 14.05.2021 | BridgeBio Pharma Receives FDA Fast Track Designation For Investigational Gene Therapy For Congenital Adrenal Hyperplasia | Preclinical Data for Congenital Adrenal Hyperplasia and Canavan Disease Programs Shared at American Society of Gene & Cell Therapy Annual Meeting, Enabling Anticipated Clinical Trials This Year PALO ALTO, CA – May 14, 2021 — BridgeBio P... |
| 11.05.2021 | Talaris Therapeutics Announces Closing of Initial Public Offering | BOSTON and LOUISVILLE, KY – May 11, 2021 – Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certa... |
| 20.04.2021 | Biomea Announces Closing of Initial Public Offering | REDWOOD CITY, CA – April 20, 2021 – Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients w... |